CNQ topped the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other.

DOV lowers its 2024 adjusted EPS view to $8.08-$8.18 for 2024 from $9.05-$9.20 to exclude the impacts of the ESG business ...

Building a successful investment portfolio takes skill and hard work, no matter if you're a growth, value, income, or momentum-focused investor. How do you find the right combination of stocks that ...

Las Vegas Sands Corp. LVS reported lower-than-expected third-quarter 2024 results, with earnings and net revenues missing the ...

Recently, Zacks.com users have been paying close attention to Oracle (ORCL). This makes it worthwhile to examine what the ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Among the seven companies, Tesla is going to be the first to report, with its earnings release scheduled after market close ...

Investment analysts at Zacks Research upped their Q3 2025 earnings per share estimates for Allegion in a research report ...

The consensus estimate for Baker Hughes’ current full-year earnings is $2.25 per share. Zacks Research also issued estimates for Baker Hughes’ FY2025 earnings at $2.59 EPS, Q3 2026 earnings at $0.79 ...

Recently, Zacks.com users have been paying close attention to Visa (V). This makes it worthwhile to examine what the stock has in store.

Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Recently, Zacks.com users have been paying close attention to Palantir Technologies (PLTR). This makes it worthwhile to examine what the stock has in store.